In8Bio

In8Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.
Looking for a particular In8Bio employee's phone or email?

In8bio Questions

News

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications - GlobeNewswire

IN8bio Presents T cell Engager Data Demonstrating Deep B Cell Depletion for Autoimmune Indications GlobeNewswire

IN8bio (NASDAQ: INAB) reports INB-619 preclinical data complete B cell depletion, low IL-6 - Stock Titan

IN8bio (NASDAQ: INAB) reports INB-619 preclinical data complete B cell depletion, low IL-6 Stock Titan

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial - Yahoo Finance

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial Yahoo Finance

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - Yahoo Finance

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Yahoo Finance

Breakthrough AML Treatment: IN8bio's Cell Therapy Achieves Perfect Remission Rate in Phase 1 - Stock Titan

Breakthrough AML Treatment: IN8bio's Cell Therapy Achieves Perfect Remission Rate in Phase 1 Stock Titan

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire

IN8bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights GlobeNewswire

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 - Yahoo Finance

IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 Yahoo Finance

Why In8bio took its time moving into autoimmunity - FirstWord Pharma

Why In8bio took its time moving into autoimmunity FirstWord Pharma

IN8bio Secures FDA Guidance on Bringing Gamma-Delta T-cell Therapy INB-100 to Pivotal AML Trial - CGTLive®

IN8bio Secures FDA Guidance on Bringing Gamma-Delta T-cell Therapy INB-100 to Pivotal AML Trial CGTLive®

EHA 2024 – In8bio bets on a registrational plan | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

EHA 2024 – In8bio bets on a registrational plan | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy - Fierce Biotech

IN8bio halts phase 2 glioblastoma trial, lays off half of workforce to focus on leukemia cell therapy Fierce Biotech

IN8bio Inc. (INAB) reports earnings - qz.com

IN8bio Inc. (INAB) reports earnings qz.com

IN8bio cuts staff and pipeline to focus on AML cell therapy - Pharmaceutical Technology

IN8bio cuts staff and pipeline to focus on AML cell therapy Pharmaceutical Technology

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients - Yahoo Finance

IN8bio Reports Updated Positive Results from Phase 1 Trial of INB-100 in Leukemia Patients Yahoo Finance

IN8bio’s Gamma-Delta T-cell Therapy INB-100 Helps Maintain Complete Remissions After HSCT in Patients With Hematologic Malignancies - CGTLive®

IN8bio’s Gamma-Delta T-cell Therapy INB-100 Helps Maintain Complete Remissions After HSCT in Patients With Hematologic Malignancies CGTLive®

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 - GlobeNewswire

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 GlobeNewswire

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases - GlobeNewswire

IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases GlobeNewswire

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival - Yahoo Finance

IN8bio Presents Positive Phase 1 Data of INB-200 in Newly Diagnosed GBM Demonstrating Prolonged Progression-Free Survival Yahoo Finance

IN8bio to Lay Off About 49% of Employees - BioSpace

IN8bio to Lay Off About 49% of Employees BioSpace

INAB - In8Bio, Inc. Latest Stock News & Market Updates - Stock Titan

INAB - In8Bio, Inc. Latest Stock News & Market Updates Stock Titan

IN8bio Announces 1-for-30 Reverse Stock Split - TipRanks

IN8bio Announces 1-for-30 Reverse Stock Split TipRanks

IN8bio Regains Nasdaq Compliance with Bid Price Rule - TipRanks

IN8bio Regains Nasdaq Compliance with Bid Price Rule TipRanks

IN8bio : Corporate Presentation November 2025 - MarketScreener

IN8bio : Corporate Presentation November 2025 MarketScreener

IN8bio Appoints Kenneth LaMontagne, Ph.D., to Lead Business Development - citybiz

IN8bio Appoints Kenneth LaMontagne, Ph.D., to Lead Business Development citybiz

IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors - GlobeNewswire

IN8bio Appoints Emily Fairbairn and Luba Greenwood to Board of Directors GlobeNewswire

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer - citybiz

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer citybiz

INAB IPO News - Gamma-delta T cell biotech IN8bio relaunches $44 million IPO - renaissancecapital.com

INAB IPO News - Gamma-delta T cell biotech IN8bio relaunches $44 million IPO renaissancecapital.com

IN8bio Appoints Alan S. Roemer as Chairman - citybiz

IN8bio Appoints Alan S. Roemer as Chairman citybiz

Coulter Partners places Board Director at IN8bio - PharmiWeb.com

Coulter Partners places Board Director at IN8bio PharmiWeb.com

INAB Stock Price and Chart — NASDAQ:INAB - TradingView

INAB Stock Price and Chart — NASDAQ:INAB TradingView

Incysus Therapeutics to Present at Solebury Trout Private Company Showcase - GlobeNewswire

Incysus Therapeutics to Present at Solebury Trout Private Company Showcase GlobeNewswire

IN8bio (NASDAQ:INAB) Upgraded at Zacks Research - Defense World

IN8bio (NASDAQ:INAB) Upgraded at Zacks Research Defense World

Top In8Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant